Nanoparticle 'cluster-bomb' targets tumors to reduce chemo doses


A team of scientists from the U.S. and China have devised a type of nanoparticle containing yet more nanoparticles, which together form a "cluster-bomb" to improve tumor penetration.

The researchers from the University of Science and Technology of China along with those from Georgia Tech and Emory University packed the chemotherapy drug cisplatin into nanoparticles just 5 nanometers in diameter and then packed those particles into a relatively larger nanoparticle 100 nanometers wide. The larger vehicle allowed for the safe transport across leaky blood vessels at the tumor site, which tends to be of higher acidity than healthier parts of the body and breaks down the 100-nanometer particle, releasing the smaller ones.

These smaller, drug-carrying particles then penetrate the tumor cells, ultimately releasing the cisplatin, which kills the cells from the inside via platinum-based cross-linking. Normally, cisplatin is quite toxic when it reaches healthy organs, but the targeted approach decreased the toxicity significantly.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

In mice with human pancreatic tumors, the clustered particle enhanced cisplatin accumulation in the cancer cells. With the same dose resulting in 7 times the amount of cisplatin in the tumor, treatments would not have to be as limited to achieve the same outcome. And the nanotech approach also demonstrated effectiveness in lung cancer and breast cancer models that normally do not respond to cisplatin, prolonging survival by weeks.

The researchers published their results in the journal PNAS.

"The negative side effects of cisplatin are a long-standing limitation for conventional chemotherapy," team member Jinzhi Du said in a statement. "In our study, the delivery system was able to improve tumor penetration to reach more cancer cells, as well as release the drugs specifically inside cancer cells through their size-transition property."

- here's the release
- and here's the study abstract

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.